BCLSI
KLRA

Bain Capital Life Sciences Investors’s Kailera Therapeutics KLRA Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio KLRA Stock Details KLRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$498M Buy
+22,583,268
New +$496M 29.58% 1

Other funds holding KLRA

BCI
Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bain Capital Life Sciences Investors's KLRA Position: Q2 2026 in Review

Bain Capital Life Sciences Investors opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 22,583,268 shares worth $498M. The stake represents 29.58% of the portfolio and ranks #1 among its holdings.

85 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

  • Bain Capital Life Sciences Investors held 22,583,268 shares of Kailera Therapeutics worth $498M as of Q2 2026.
  • Kailera Therapeutics was a new Bain Capital Life Sciences Investors position in Q2 2026.
  • Kailera Therapeutics made up 29.58% of Bain Capital Life Sciences Investors's portfolio in Q2 2026, its #1 holding.
  • 85 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2026, filed 14 Aug 2026.